Syngene International Ltd. News and Updates

Name: Latest research reports of Syngene International Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Syngene International Ltd.
Rating: 5
Author: ICICI Securities Limited

Keep track of all breaking news on Syngene International Ltd. from all sources in a single place.

Load latest

Syngene International Ltd.

23 Jul 2018

645.80

-1.45%

Biocon arm Syngene expands scope of R&D; work with Baxter Health Corp

Business Line

Syngene International, the contract research arm of Biocon has expanded the scope of its research and development (R&D) efforts with Baxter Health

Syngene International Ltd.'s price crossed below 30Day SMA today

Syngene International Ltd.

30 May 2018

645.80

-1.45%

Syngene International inks pact with Zumutor Biologics

Business Line

Syngene International on Wednesday informed the bourses that it has entered into a pact with US-based Zumutor Biologics for biotherapeutic antibody di

Syngene International Ltd. has lost -29.02% in the last 1 Year

Syngene International Ltd.

18 May 2018

645.80

-1.45%

Biocon sells 1.88% stake in Syngene for Rs230 crore

livemint

Syngene International promoter Biocon says it has sold 37,65,574 equity shares of Syngene amounting to 1.88% through open market sale

Syngene International Ltd.'s price crossed below 50Day SMA today

Biocon sells 2% stake in Syngene for Rs 2.3 bn through open-market sale

Business Standard | 18 May 2018

Syngene International Ltd.

27 Apr 2018

645.80

-1.45%

Syngene International Ltd

Buy: Syngene International Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 41% YoY to | 409 crore (I-direct estimates: | 381 crore) mainly due to lower base of Q4FY17 (fire incident impact) and strong growth in chemical development and discovery services supported by biologics business EBITDA margins declined 281 bps to 31.6% YoY (I-direct estimate: 33.1%) mainly due to higher other expenses. EBITDA increased 29% YoY to | 129 crore (I-direct estimates: | 126 crore...

Syngene Internationa.. has an average target of 1030.00 from 1 broker.

Syngene International Ltd.

26 Mar 2018

645.80

-1.45%

Syngene inks pact with GSK for new drug discovery

Business Line

Syngene International on Monday signed a research and development agreement with global healthcare company GSK. As part of the agreement, Syngene will set up a customised discovery

Number of FII/FPI investors decreased from 332 to 279 in Jun 2025 qtr

Biocon's Syngene inks pact with GSK for new drug discovery

Business Standard | 26 Mar 2018 2 more

Syngene International Ltd.

30 Jan 2018

645.80

-1.45%

Result Update:Syngene Intl.

Hold: Syngene International Ltd.

Axis Direct

Syngene posted strong Q3 revenue growth of 17% YoY (~5% ahead of our estimate). EBITDA margin at 32.5% was weighed down by higher growth in staff cost (19% YoY) and other expenses (24% YoY).

Syngene International Ltd. is trading below all available SMAs

Syngene International Ltd.

29 Jan 2018

645.80

-1.45%

Syngene International Ltd

Buy: Syngene International Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 17% YoY to | 388 crore, above I-direct estimate of | 372 crore, driven by a strong performance in the chemicals business from the development & manufacturing vertical and continued traction in the discovery vertical EBITDA margins declined 144 bps to 32.5% YoY (I-direct estimate: 33%) mainly due to higher employee and other expenses. EBITDA grew 12% YoY to | 126.1 crore (I-direct estimate: | 123 crore)...

Syngene International Ltd. is trading below all available SMAs

Syngene International Ltd.

10 Jan 2018

645.80

-1.45%

Visit Note:Syngene Intl.

Mgmt Note: Syngene International Ltd.

Axis Direct

Syngene is expected to post stronger growth from H2FY18 given (1) most of the business impacted by fire incident in Dec'16 will be generating revenue from Q3/ Q4FY18, (2) addition of large scale commercial manufacturing of intermediates and API's for innovator companies

Syngene International Ltd. is trading below all available SMAs

Syngene International Ltd.

14 Nov 2017

645.80

-1.45%

Syngene International Limited

Business Line

Syngene International has expanded its ongoing drug discovery and development operations with its US-based partner Bristol-Myers Squibb till 2026, the company said in a notice to the stock exchanges.

Syngene International Ltd. has lost -29.02% in the last 1 Year

Syngene International Ltd.

02 Nov 2017

645.80

-1.45%

Result Update:Syngene Intl.

Hold: Syngene International Ltd.

Axis Direct

Q2FY18 revenue grew 11% YoY (14% in cc terms), as growth is accelerating after the fire incident (6% YoY in Q1). EBITDA margin was healthy at 33.9% despite 22% YoY growth in staff cost and 14% YoY growth in other expenses. Revenue grew 12% YoY in cc terms in H1FY18.